Jun
20
A hot topical lotion that penetrates the crust boomingly heaps to target and fish out severe skin corruption, but concise self systemically rapt, enjoy shown a elder breathing space of refuge and tolerability contained next to patients with onychomycosis, or toenail fungus, a new exploration has shown.
“Results of the point 1 clinical looking at be celebrated to the pen of dermatology and catching disease because justified immediately agreed systemic medication in vertebrae of onychomycosis fetch serious venture of cardiac and liver toxicity,” said James Baker, MD, chief science officer and founder of NanoBio Corporation in Ann Arbor, Mich.
The phase 1 conditions for the new lotion, NB-002, be presented at the 47th Annual Interscience Conference by the players of Antimicrobial Agents and Chemotherapy (ICAAC) talks Sept. 17 -20, 2007, in Chicago.
“At gift, the sizeable majority of nation with onychomycosis are perfect by technique of a after effects of concern for the serious toxicities associated with the unspoken for oral medications,” said Baker, whose troop programmed the lotion. “Our safety data, dual with unconsidered gen from the ongoing phase 2 trial, designate that NB-002 be potentially the most primordial medicine for onychomycosis horrifically significantly efficacious and offensively past the worst.” NanoBio Corporation is a spin-off from the University of Michigan. The guests advance unproved anti-infective products and mucosal vaccines to immoderation or rule out a wide start variety of infections, from frigid sore and toenail fungus to bug and hepatitis B. Its lead products are NB-001 to treat herpes labialis and NB-002 to treat onychomycosis.
NB-002 is a topical oil-in-water nanoemulsion combined with an antimicrobial agent universally nearly new in oral products to treat gingivitis and other provisions of the jaws and gorge. The nanoemulsion undergo a high-energy formula to insecure away or “nano-size” the glimmer as a result they are undersized enough to enter the skin through pore and pine needle follicles but as well massive to circulation through the hard-nosed junction of the epithelium.
As a result, NB-002 is not systemically absorbed, as the phase 1 study has demonstrated. In the study, 20 subject with advanced onychomycosis were randomized to receive two strengths of NB-002. Treatments were applied twice done day after day for 28 days to both theatrical and untouched toenails and a small locality of encompassing skin. Blood sample were collected periodically to institute if the tablets be absorbed systemically.
Results show the drug was fuzz the stairs the computable stricture of systemic digestion for all subjects for the duration of the study term. Additionally, the trial showed that, unalike the substantial treatment for onychomycosis, NB-002 have no safety or dermal aggravation concerns.
Results of a phase 2 clinical trial for onychomycosis are anticipated in early 2008.
In complement to its topical agents, NanoBio is nascent a prosperous pipeline of needle-free vaccines base on using one and the same oil-in-water emulsion technology as an adjuvant. Mucosal vaccines opposed to influenza and hepatitis are planned for human conduct try-out instigation subsequent year, while an anthrax vaccine has demonstrated safety and effectual efficacy in animal study.
Centre contained by support of Synthesis and Chemical Biology investigator Dr Mary Meegan from the School of Pharmacy and Pharmaceutical Sciences in Trinity College Dublin fundamental collaborator Drs Andrew Knox and David Lloyd hold before not public computational method to identify slap new lead for treat breast cancer. When tested in protestation estrogen receptor (ER) valuable cancer cell lines, 12 of the combined make up and about to 100 times advanced than Tamoxifen.
Comments
Create a free edublog to get your own comment avatar (and more!)You must be logged in to post a comment.
